A group of researchers proposes a framework that translates a woman’s absolute risk of breast cancer into a specific interval between mammograms. The idea is simple to state and hard to put into practice: if risk is going to decide how often to screen, there has to be a common rule that does not depend on which risk model a programme happens to use.
What was known
Precision screening trials —those that tailor mammography frequency to individual risk— use different risk models, different risk strata and different intervals. There is no consensus on how to turn a percentage of absolute risk into a recommendation for how often to repeat the test. That lack of a shared rule makes it hard to compare trials with one another and to move their findings into routine care.
What this study adds
The authors develop and evaluate a framework they describe as risk-model-agnostic: rather than starting from a particular calculation tool, it starts from the absolute-risk cut points already defined in clinical guidelines and maps them to screening intervals. The work focuses on women in the United States, and its main outcome is the screening interval and frequency derived from absolute risk. The stated aim is to guide the design of future personalised screening trials and to help that design reach routine practice.
Main results
The framework produced a gradient of intervals that scales with absolute risk: annual screening for risks of 2% to 3%; annual screening with supplemental imaging and counselling for risks of 3% or higher; biennial screening for risks of 1% to 2%; and, below that level, potentially longer intervals. When these assignments were compared with those of ongoing intervention trials, the intervals used in the trials varied widely and were not uniformly aligned with absolute-risk levels, underscoring the absence of a standardised mapping between risk and screening intensity.
What it means
The framework does not say which risk model is best, nor which interval a particular woman should receive; it offers an explicit, transparent rule linking calculated risk to screening frequency. According to the authors, that mapping may improve consistency across trials and facilitate equitable implementation of precision screening in different population settings. For a woman, the practical reading is that the conversation about when the next mammogram is due gains a shared language, even though the decision still rests on each woman’s clinical history.
Reading from the breast unit
A framework like this requires agreement on two things before anything changes: which risk tool is used and which cut points are applied. Without that prior agreement, two professionals can calculate similar risks and recommend different intervals. It also reminds us that intensifying screening in higher-risk groups carries a resource cost that needs planning.
Reference: Jiang S, Bennett DL, Rosner B, Colditz GA. Translating absolute risk of breast cancer into screening frequency: a framework to guide practice. Journal of the National Cancer Institute, 2026. DOI
